Article Details

AMO Pharma to Participate in Myotonic Dystrophy Foundation "Meet the DM Drug Developers ...

Retrieved on: 2021-03-03 19:18:45

Tags for this article:

Click the tags to see associated articles and topics

AMO Pharma to Participate in Myotonic Dystrophy Foundation "Meet the DM Drug Developers .... View article details on hiswai:

Excerpt

... study to assess the efficacy and safety of AMO-02, a dual action investigational mRNA modulating/GSK3ß kinase inhibitor, in the treatment of CDM1.

Article found on: www.prnewswire.co.uk

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up